Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus HYDRO SERP 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus HYDRO SERP 50.
ALDORIL 15 vs HYDRO-SERP "50"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Hydrochlorothiazide 50 mg orally once daily.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination